CN113710259B - 作为有效的癌症疗法的合胞溶瘤性单纯疱疹突变体 - Google Patents

作为有效的癌症疗法的合胞溶瘤性单纯疱疹突变体 Download PDF

Info

Publication number
CN113710259B
CN113710259B CN202080032165.0A CN202080032165A CN113710259B CN 113710259 B CN113710259 B CN 113710259B CN 202080032165 A CN202080032165 A CN 202080032165A CN 113710259 B CN113710259 B CN 113710259B
Authority
CN
China
Prior art keywords
hsv
protein
seq
mut
cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN202080032165.0A
Other languages
English (en)
Chinese (zh)
Other versions
CN113710259A (zh
Inventor
蒂莫西·P·克里普
凯文·A·卡西迪
王品怡
朱莉娅·K·哈雷
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nationwide Childrens Hospital Inc
Original Assignee
Nationwide Childrens Hospital Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nationwide Childrens Hospital Inc filed Critical Nationwide Childrens Hospital Inc
Publication of CN113710259A publication Critical patent/CN113710259A/zh
Application granted granted Critical
Publication of CN113710259B publication Critical patent/CN113710259B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A61K35/763—Herpes virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C12N15/869—Herpesviral vectors
    • C12N15/8695—Herpes simplex virus-based vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/00051—Methods of production or purification of viral material
    • C12N2710/00052—Methods of production or purification of viral material relating to complementing cells and packaging systems for producing virus or viral particles
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16621—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16622—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16632—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16641—Use of virus, viral particle or viral elements as a vector
    • C12N2710/16643—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16651—Methods of production or purification of viral material

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN202080032165.0A 2019-03-14 2020-03-13 作为有效的癌症疗法的合胞溶瘤性单纯疱疹突变体 Active CN113710259B (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962818577P 2019-03-14 2019-03-14
US62/818,577 2019-03-14
US201962932725P 2019-11-08 2019-11-08
US62/932,725 2019-11-08
PCT/US2020/022806 WO2020186238A1 (en) 2019-03-14 2020-03-13 Syncytial oncolytic herpes simplex mutants as potent cancer therapeutics

Publications (2)

Publication Number Publication Date
CN113710259A CN113710259A (zh) 2021-11-26
CN113710259B true CN113710259B (zh) 2024-12-31

Family

ID=72426047

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202080032165.0A Active CN113710259B (zh) 2019-03-14 2020-03-13 作为有效的癌症疗法的合胞溶瘤性单纯疱疹突变体

Country Status (11)

Country Link
US (1) US12480097B2 (https=)
EP (1) EP3937960A4 (https=)
JP (2) JP7671253B2 (https=)
KR (1) KR102933002B1 (https=)
CN (1) CN113710259B (https=)
AU (1) AU2020235140B2 (https=)
BR (1) BR112021017651A2 (https=)
CA (1) CA3132867A1 (https=)
IL (1) IL286142B2 (https=)
SG (1) SG11202109707VA (https=)
WO (1) WO2020186238A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN120380154A (zh) * 2022-12-14 2025-07-25 Eg427公司 改良型单纯疱疹病毒1型

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001009361A1 (en) * 1999-08-03 2001-02-08 Yissum Research Development Company Of The Hebrew University Of Jerusalem Recombinant hsv-1 and live viral vaccines

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005005637A2 (en) * 2003-05-09 2005-01-20 Medigene, Inc. Herpes simplex virus comprising a genetically modified glycoprotein d
JP5639361B2 (ja) * 2006-09-08 2014-12-10 ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア Ｈｓｖ−１及びｈｓｖ−２ワクチン並びにその使用方法
JP6726824B2 (ja) * 2013-07-17 2020-07-22 ユニヴァーシティ オヴ ピッツバーグ オヴ ザ コモンウェルス システム オヴ ハイアー エデュケーション 効率的な遺伝子送達用途のための非毒性ｈｓｖベクター及びその製造のための補完細胞
JP6865736B2 (ja) * 2015-05-04 2021-04-28 ザ ブリガム アンド ウィメンズ ホスピタル インコーポレイテッドＴｈｅ Ｂｒｉｇｈａｍ ａｎｄ Ｗｏｍｅｎ’ｓ Ｈｏｓｐｉｔａｌ， Ｉｎｃ． 腫瘍溶解性ｈｓｖ１ベクターおよび使用法
US10596234B2 (en) 2016-10-28 2020-03-24 University Of Southern California Compositions and methods to inhibit viral replication
JP7490365B2 (ja) * 2017-03-09 2024-05-27 シァメン・ユニヴァーシティ 組み換え単純ヘルペスウイルス及びその使用

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001009361A1 (en) * 1999-08-03 2001-02-08 Yissum Research Development Company Of The Hebrew University Of Jerusalem Recombinant hsv-1 and live viral vaccines

Also Published As

Publication number Publication date
AU2020235140A1 (en) 2021-09-30
JP2025028186A (ja) 2025-02-28
CN113710259A (zh) 2021-11-26
JP7671253B2 (ja) 2025-05-01
KR102933002B1 (ko) 2026-03-04
JP2022524379A (ja) 2022-05-02
IL286142B2 (en) 2026-03-01
EP3937960A4 (en) 2023-03-29
IL286142B1 (en) 2025-11-01
EP3937960A1 (en) 2022-01-19
SG11202109707VA (en) 2021-10-28
KR20210139306A (ko) 2021-11-22
CA3132867A1 (en) 2020-09-17
WO2020186238A1 (en) 2020-09-17
AU2020235140B2 (en) 2026-03-26
BR112021017651A2 (pt) 2021-11-16
US12480097B2 (en) 2025-11-25
US20220154149A1 (en) 2022-05-19
IL286142A (en) 2021-10-31

Similar Documents

Publication Publication Date Title
JP7541370B2 (ja) 効率的な遺伝子送達用途のための非毒性ｈｓｖベクター及びその製造のための補完細胞
US11419926B2 (en) Identification of mutations in herpes simplex virus envelope glycoproteins that enable or enhance vector retargeting to novel non-HSV receptors
JP6817979B2 (ja) 腫瘍選択的ｅ１ａおよびｅ１ｂ変異体
AU2018230046B9 (en) Recombinant Herpes simplex virus and use thereof
JP4216350B2 (ja) 動物細胞感染用の組換えｄｎａウイルスベクター
JP7015551B2 (ja) ウイルス動態への影響を最小限にするための治療用アデノウイルスにおける外因性遺伝子発現
JP2020536510A (ja) 細胞の遺伝子修飾のための非組込みｄｎａベクター
EP0958371B1 (en) Cytopathic viruses for therapy and prophylaxis of neoplasia
US20020110543A1 (en) Viral delivery system for infectious transfer of large genomic DNA inserts
Abrams et al. Sequential deletion of genes from the African swine fever virus genome using the cre/loxP recombination system
US10806761B2 (en) Oncolytic HSV1 vector and methods of use
EP3810164A1 (en) Antigenically stealthed oncolytic viruses
CN113710259B (zh) 作为有效的癌症疗法的合胞溶瘤性单纯疱疹突变体
RU2821999C2 (ru) Синцитиальные онколитические мутанты herpes simplex в качестве мощных терапевтических средств для лечения рака
CN1509764A (zh) 一种抗癌靶向基因病毒药物的制备方法
WO2020106566A1 (en) Regulatable fusogenic oncolytic herpes simplex virus type 1 virus and methods of use
Grant et al. Engineering cell lines for production of replication defective HSV‐1 gene therapy vectors
CN121628895A (zh) 增强型特异性启动子及其应用
JP4288259B2 (ja) 動物細胞感染用の組換えｄｎａウイルスベクター
HK40063431A (en) Oncolytic hsv1 vector and methods of use
Gallaher In vivo delivery and persistence in mouse of an episomal expression cassette by a helper dependent adenovirus–Epstein-Barr virus hybrid gene therapy vector
Seereeram Manipulating gene expression in DRG sensory neurones

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant